Este é o terceiro episódio da nossa série especial realizada em parceria com a Pfizer, em que trazemos discussões que conectam ciência e prática clínica para enfrentar desafios no combate às infecções.

👉 Dê o play e confira!

#ResistênciaAntimicrobiana #GramNegativos #DiagnósticoMicrobiológico #Infectologia #Antibióticos #Carbapenemase #AmpC #PfizerPro #InfectoCast

Para mais conteúdo sobre infectologia acesse:

https://www.infectologiapro.com.br/

Referências 

DELLINGER, R. P. et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Critical Care Medicine, v. 32, n. 3, p. 858–873, mar. 2004.

YOKOTA, P. K. O. et al. Impact of Appropriate Antimicrobial Therapy for Patients with Severe Sepsis and Septic Shock – A Quality Improvement Study. PLoS ONE, v. 9, n. 11, p. e104475, 6 nov. 2014.

FERNÁNDEZ-MARTÍNEZ, N. F. et al. Risk Factors for Multidrug-Resistant Gram-Negative Bacteria Carriage upon Admission to the Intensive Care Unit. International Journal of Environmental Research and Public Health, v. 19, n. 3, p. 1039, 18 jan. 2022.

PASQUAU-LIAÑO, J. Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a stablished antimicrobial stewardship program. Revista Española de Quimioterapia, v. 35, n. Suppl3, p. 102–107, 24 out. 2022.

IM, Y. et al. Time-to-antibiotics and clinical outcomes in patients with sepsis and septic shock: a prospective nationwide multicenter cohort study. Critical Care, v. 26, n. 1, 13 jan. 2022.

GUARINO, M. et al. 2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department. Journal of Clinical Medicine, v. 12, n. 9, p. 3188–3188, 28 abr. 2023.

EVANS, L. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Medicine, v. 47, n. 11, p. 1181–1247, 2 out. 2021.

Shi Y, Wu J, Mi W, Zhang X, Ren X, Shen C, Lu C. Ceftazidime-avibactam induced renal disorders: past and present. Front Pharmacol. 2024 Jan 22;15:1329307. doi: 10.3389/fphar.2024.1329307. PMID: 38318141; PMCID: PMC10838962.